Friday, Jan. 31, 2025

12 noon EST/9 am PST
via Zoom

Please join The Leukemia & Lymphoma Society's (LLS) Therapy Acceleration Program® (TAP) for a live one-hour discussion panel.

Hear from LLS TAP staff and biotech partners who are united to accelerate cures for patients with AML.

Agenda:

Introduction
Moderated discussion with LLS staff and TAP company partners:
- Lawrence Mayer, PhD – Celator Pharmaceuticals
- Ashley Yocum, PhD – LLS Beat AML
- Ann Collins, PA – LLS PedAL
- Stephan Braun, MD, PhD – ImCheck Therapeutics
Q&A

How is LLS leading the way in AML research?

More than 20% of the biomedical research funded by LLS is aimed at finding cures and improving quality of life for patients with AML—that’s $75 million!
Therapy Acceleration Program (TAP) – more than 10 clinical trials in AML currently in development with 7 biotech partners
Beat AML Master Clinical Trial - continues to grow by testing precision medicine for adults with AML, exploring ways to reduce side effects and improve patients’ quality of life and making clinical trials more patient friendly
Pediatric Acute Leukemia (PedAL) Master Clinical Trial - matches children with AML to precision medicine therapies; screening trials are open globally

United in Action to Accelerate Cures for Patients with AML